Acceleration of diabetic-wound healing with PEGylated rhaFGF in healing-impaired streptozocin diabetic rats

Wound Repair and Regeneration

Volumn 19, Issue 5, 2011, Pages 633-644

  Huang, Zhifeng ^a,b   Lu, Meifei ^a   Zhu, Guanghui ^a   Gao, Hongchang ^a   Xie, Liyun ^a   Zhang, Xiaoqin ^a   Ye, Chaohui ^a   Wang, Yan ^a   Sun, Chuanchuan ^a   Li, Xiaokun ^a,c  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b NANJING UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c Basic Medical College   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLINE; RECOMBINANT FIBROBLAST GROWTH FACTOR; SEPHAROSE; STREPTOZOCIN; TRANSFORMING GROWTH FACTOR BETA;

AFFINITY CHROMATOGRAPHY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CELL PROLIFERATION; CELL STRAIN 3T3; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GEL FILTRATION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MITOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; SKIN CELL; SKIN INJURY; TEMPERATURE MEASUREMENT; THERMOSTABILITY; TREATMENT RESPONSE; WOUND HEALING IMPAIRMENT;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DRUG STABILITY; FEMALE; FIBROBLAST GROWTH FACTOR 1; MALE; MICE; POLYETHYLENE GLYCOLS; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; SKIN; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; WOUND HEALING;

EID: 80052756089     PISSN: 10671927     EISSN: 1524475X     Source Type: Journal    
DOI: 10.1111/j.1524-475X.2011.00722.x     Document Type: Article

References (31)

1. Brem H, Tomic-Canic M,. Cellular and molecular basis of wound healing in diabetes. J Clin Invest 2007; 117: 1219-22. (Pubitemid 46718408)
2. Blakytny R, Jude EB, Martin GJ, Boulton AJ, Ferguson MW,. Lack of insulin-like growth factor 1 (IGF1) in the basal keratinocyte layer of diabetic skin and diabetic foot ulcers. J Pathol 2000; 190: 589-94. (Pubitemid 30164489)
3. Jude EB, Blakytny R, Bulmer J, Boulton AJ, Ferguson MW,. Transforming growth factor-beta 1, 2, 3 and receptor type I and II in diabetic foot ulcers. Diabet Med 2002; 19: 440-7. (Pubitemid 34639153)
4. Lobmann R, Schultz G, Lehnert H,. [Molecular fundamentals of wound healing in diabetic foot syndrome]. Med Klin (Munich) 2003; 98: 292-301. (Pubitemid 36578223)
5. Galkowska H, Wojewodzka U, Olszewski WL,. Chemokines, cytokines, and growth factors in keratinocytes and dermal endothelial cells in the margin of chronic diabetic foot ulcers. Wound Rep Regen 2006; 14: 558-65. (Pubitemid 44470072)
6. Pradhan L, Nabzdyk C, Andersen ND, LoGerfo FW, Veves A,. Inflammation and neuropeptides: the connection in diabetic wound healing. Expert Rev Mol Med 2009; 11: e2.
7. Papanas N, Maltezos E,. The diabetic foot: established and emerging treatments. Acta Clin Belg 2007; 62: 230-8. (Pubitemid 47234752)
8. Sellke FW, Li J, Stamler A, Lopez JJ, Thomas KA, Simons M,. Angiogenesis induced by acidic fibroblast growth factor as an alternative method of revascularization for chronic myocardial ischemia. Surgery 1996; 120: 182-8. (Pubitemid 26287802)
9. Inada Y, Furukawa M, Sasaki H, Kodera Y, Hiroto M, Nishimura H, Matsushima A,. Biomedical and biotechnological applications of PEG- and PM-modified proteins. Trends Biotechnol 1995; 13: 86-91.
10. DeSantis G, Jones JB,. Chemical modification of enzymes for enhanced functionality. Curr Opin Biotechnol 1999; 10: 324-30. (Pubitemid 29373944)
11. Roberts MJ, Bentley MD, Harris JM,. Chemistry for peptide and protein PEGylation. Adv Drug Deliv Rev 2002; 54: 459-76. (Pubitemid 34615543)
12. Xiao J, Burn A, Tolbert TJ,. Increasing solubility of proteins and peptides by site-specific modification with betaine. Bioconjug Chem 2008; 19: 1113-8. (Pubitemid 351874930)
13. Marsac Y, Cramer J, Olschewski D, Alexandrov K, Becker CF,. Site-specific attachment of polyethylene glycol-like oligomers to proteins and peptides. Bioconjug Chem 2006; 17: 1492-8. (Pubitemid 44851494)
14. Kinstler O, Molineux G, Treuheit M, Ladd D, Gegg C,. Mono-N-terminal poly(ethylene glycol)-protein conjugates. Adv Drug Deliv Rev 2002; 54: 477-85. (Pubitemid 34615544)
15. Lee BK, Kwon JS, Kim HJ, Yamamoto S, Lee EK. Solid-phase PE,. Gylation of recombinant interferon alpha-2a for site-specific modification: process performance, characterization, and in vitro bioactivity. Bioconjug Chem 2007; 18: 1728-34. (Pubitemid 350219969)
16. Niall HD,. Automated Edman degradation: the protein sequenator. Methods Enzymol 1973; 27: 942-1010.
17. Morjana N, Tal R,. Expression and equilibrium denaturation of cardiac troponin I: stabilization of a folding intermediate during denaturation by urea. Biotechnol Appl Biochem 1998; 28: 7-17. (Pubitemid 28369900)
18. Jameson J, Ugarte K, Chen N, Yachi P, Fuchs E, Boismenu R, Havran WL,. A role for skin gammadelta T cells in wound repair. Science 2002; 296: 747-9. (Pubitemid 34442005)
19. Miki T, Bottaro DP, Fleming TP, Smith CL, Burgess WH, Chan AM, Aaronson SA,. Determination of ligand-binding specificity by alternative splicing: two distinct growth factor receptors encoded by a single gene. Proc Natl Acad Sci U S A 1992; 89: 246-50.
20. Kitamura K, Takahashi T, Takashina K, Yamaguchi T, Noguchi A, Tsurumi H, Toyokuni T, Hakomori S,. Polyethylene glycol modification of the monoclonal antibody A7 enhances its tumor localization. Biochem Biophys Res Commun 1990; 171: 1387-94. (Pubitemid 20318105)
21. Veronese FM, Mero A, Caboi F, Sergi M, Marongiu C, Pasut G,. Site-specific pegylation of G-CSF by reversible denaturation. Bioconjug Chem 2007; 18: 1824-30. (Pubitemid 350219980)
22. Cai L, Wang Y, Zhou G, Chen T, Song Y, Li X, Kang YJ,. Attenuation by metallothionein of early cardiac cell death via suppression of mitochondrial oxidative stress results in a prevention of diabetic cardiomyopathy. J Am Coll Cardiol 2006; 48: 1688-97. (Pubitemid 44528172)
23. Song Y, Wang J, Li Y, Du Y, Arteel GE, Saari JT, Kang YJ, Cardiac CL,. Metallothionein synthesis in streptozotocin-induced diabetic mice, and its protection against diabetes-induced cardiac injury. Am J Pathol 2005; 167: 17-26. (Pubitemid 40884766)
24. Cheng B, Liu HW, Fu XB, Sun TZ, Sheng ZY,. Recombinant human platelet-derived growth factor enhanced dermal wound healing by a pathway involving ERK and c-fos in diabetic rats. J Dermatol Sci 2007; 45: 193-201. (Pubitemid 46231239)
25. Kurfurst MM,. Detection and molecular weight determination of polyethylene glycol-modified hirudin by staining after sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Anal Biochem 1992; 200: 244-8.
26. Huang Z, Ni C, Chu Y, Wang S, Yang S, Wu X, Wang X, Li X, Feng W, Lin S,. Chemical modification of recombinant human keratinocyte growth factor 2 with polyethylene glycol improves biostability and reduces animal immunogenicity. J Biotechnol 2009; 142: 242-9.
27. Pasut G, Veronese FM,. PEG conjugates in clinical development or use as anticancer agents: an overview. Adv Drug Deliv Rev 2009; 61: 1177-88.
28. Veronese FM, Mero A,. The impact of PEGylation on biological therapies. Biodrugs 2008; 22: 315-29.
29. Kuan CT, Wang QC, Pastan I,. Pseudomonas exotoxin A mutants. Replacement of surface exposed residues in domain II with cysteine residues that can be modified with polyethylene glycol in a site-specific manner. J Biol Chem 1994; 269: 7610-6. (Pubitemid 24217971)
30. Lee VH,. Advanced Drug Delivery Reviews: cornerstone in the stimulation and dissemination of innovative drug delivery research. Adv Drug Deliv Rev 2004; 56: 1-2. (Pubitemid 38045418)
31. Caliceti P, Veronese FM,. Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Adv Drug Deliv Rev 2003; 55: 1261-77. (Pubitemid 37464561)